EA200201030A1 - Карбаматные ингибиторы каспазы и их использование - Google Patents
Карбаматные ингибиторы каспазы и их использованиеInfo
- Publication number
- EA200201030A1 EA200201030A1 EA200201030A EA200201030A EA200201030A1 EA 200201030 A1 EA200201030 A1 EA 200201030A1 EA 200201030 A EA200201030 A EA 200201030A EA 200201030 A EA200201030 A EA 200201030A EA 200201030 A1 EA200201030 A1 EA 200201030A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- caspase
- carbamatic
- caspase inhibitors
- inhibitors
- snson
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/26—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a double bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
- C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
- C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
- C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/30—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with acyl radicals attached to the ring nitrogen atom
Abstract
Настоящее изобретение относится к ингибиторам каспазы формулы Iгде Z представляет кислород или серу; Rпредставляет водород, -CHN, -R, -CHOR, -CHSR или -СН; Y представляет электроотрицательную уходящую группу; Rпредставляет СОН, СНСОН или их сложные эфиры, амиды или изостеры; Rпредставляет группу, способную встраиваться в S2-субсайт каспазы; Rи R, взятые вместе с находящимся между ними азотом, образуют гетероциклическое кольцо и R имеет значения, указанные в описании. Соединения являются эффективными ингибиторами апоптоза и секреции IL-1β.Отчет о международном поиске был опубликован 2002.05.23.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19282600P | 2000-03-29 | 2000-03-29 | |
PCT/US2001/010182 WO2001072707A2 (en) | 2000-03-29 | 2001-03-29 | Carbamate caspase inhibitors and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200201030A1 true EA200201030A1 (ru) | 2003-02-27 |
EA005740B1 EA005740B1 (ru) | 2005-06-30 |
Family
ID=22711181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200201030A EA005740B1 (ru) | 2000-03-29 | 2001-03-29 | Карбаматные ингибиторы каспазы и их использование |
Country Status (32)
Country | Link |
---|---|
US (2) | US6689784B2 (ru) |
EP (1) | EP1268425B1 (ru) |
JP (2) | JP4298200B2 (ru) |
KR (1) | KR100858640B1 (ru) |
CN (2) | CN1994298A (ru) |
AR (1) | AR027993A1 (ru) |
AT (1) | ATE384695T1 (ru) |
AU (2) | AU4961901A (ru) |
BG (1) | BG107136A (ru) |
BR (1) | BR0109588A (ru) |
CA (1) | CA2403959A1 (ru) |
CZ (1) | CZ20023227A3 (ru) |
DE (1) | DE60132567T2 (ru) |
DK (1) | DK1268425T3 (ru) |
EA (1) | EA005740B1 (ru) |
EE (1) | EE200200550A (ru) |
ES (1) | ES2296742T3 (ru) |
HK (1) | HK1052355B (ru) |
HR (1) | HRP20020782A2 (ru) |
HU (1) | HUP0301472A3 (ru) |
IL (2) | IL151829A0 (ru) |
MX (1) | MXPA02009633A (ru) |
NO (1) | NO325062B1 (ru) |
NZ (1) | NZ521639A (ru) |
PE (1) | PE20011267A1 (ru) |
PL (1) | PL201081B1 (ru) |
PT (1) | PT1268425E (ru) |
SK (1) | SK13922002A3 (ru) |
TW (1) | TWI318207B (ru) |
WO (1) | WO2001072707A2 (ru) |
YU (1) | YU73702A (ru) |
ZA (1) | ZA200207483B (ru) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000061542A1 (en) | 1999-04-09 | 2000-10-19 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
IL148426A0 (en) | 1999-08-27 | 2002-09-12 | Cytovia Inc | α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
ATE384695T1 (de) * | 2000-03-29 | 2008-02-15 | Vertex Pharma | Carbamat caspase inhibitoren und deren verwendung |
PE20011350A1 (es) | 2000-05-19 | 2002-01-15 | Vertex Pharma | PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE) |
US20040192889A1 (en) * | 2001-03-30 | 2004-09-30 | Dale Bredesen | Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
CA2447999C (en) | 2001-05-23 | 2011-04-26 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
US7410956B2 (en) | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
WO2003088917A2 (en) * | 2002-04-19 | 2003-10-30 | Vertex Pharmaceuticals Incorporated | Regulation of tnf-alpha |
EP1447093A1 (en) * | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
JPWO2004073742A1 (ja) * | 2003-02-24 | 2006-06-01 | 第一製薬株式会社 | B型肝炎ウイルスx相互作用蛋白質の分解阻害剤 |
AU2003902704A0 (en) * | 2003-05-29 | 2003-06-19 | Crc For Waste Management And Pollution Control Limited Of Unsw | Process for producing a nanoscale zero-valent metal |
CN102225936B (zh) | 2004-03-12 | 2013-09-11 | 弗特克斯药品有限公司 | 制备化合物的方法 |
US7544855B2 (en) * | 2004-04-23 | 2009-06-09 | Buck Institute | Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664 |
NZ588448A (en) * | 2004-05-15 | 2012-01-12 | Vertex Pharma | Treating seizures using interleukin-1beta converting enzyme (ICE) inhibitors |
KR100619440B1 (ko) | 2004-05-20 | 2006-09-08 | 한기종 | 포름아마이드 유도체 제조방법 |
US7531570B2 (en) * | 2004-05-27 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Treatment of diseases using ICE inhibitors |
KR100619439B1 (ko) | 2004-05-27 | 2006-09-08 | 한기종 | 포밀기 도입된 아민유도체의 제조방법 |
US8012751B2 (en) * | 2005-03-31 | 2011-09-06 | Wisconsin Alumni Research Foundation | Differentiation of pluripotent embryonic stem cells |
KR20080038369A (ko) * | 2005-07-28 | 2008-05-06 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제 억제제 프로드럭 |
WO2007043388A1 (ja) | 2005-10-07 | 2007-04-19 | Matsushita Electric Industrial Co., Ltd. | 音響信号処理装置および音響信号処理方法 |
AU2006349611A1 (en) | 2005-11-30 | 2008-05-02 | Massachusetts Institute Of Technology | Pathogen-detecting cell preservation systems |
EP2049139A4 (en) * | 2006-04-24 | 2009-06-24 | Gloucester Pharmaceuticals Inc | TREATMENT OF TUMORS EXPRESSING RAS |
AU2007273035A1 (en) * | 2006-07-07 | 2008-01-17 | The Board Of Trustees Of The Leland Stanford Junior University | Selective caspase inhibitors |
WO2008021745A2 (en) * | 2006-08-16 | 2008-02-21 | Itherx Pharmaceuticals, Inc. | Hepatitis c virus entry inhibitors |
US20080131398A1 (en) * | 2006-08-21 | 2008-06-05 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
WO2008137567A1 (en) * | 2007-05-01 | 2008-11-13 | Cedars-Sinai Medical Center | Caspase inhibitors in the treatment of infection-associated preterm delivery |
KR101009588B1 (ko) * | 2008-06-04 | 2011-01-20 | 거진산업주식회사 | 미세여과막을 이용한 부유고형물 처리장치 |
JP2012051804A (ja) * | 2008-12-26 | 2012-03-15 | Kyoto Univ | Eg5阻害剤 |
KR101010350B1 (ko) * | 2009-03-26 | 2011-01-25 | 삼성중공업 주식회사 | 역세척 여과장치 |
WO2012061785A2 (en) | 2010-11-05 | 2012-05-10 | Brandeis University | Ice inhibiting compounds and uses thereof |
TW201236239A (en) | 2010-11-16 | 2012-09-01 | Solvay | Rechargeable metal or metal-ion cell |
EP2490021A1 (en) | 2011-02-18 | 2012-08-22 | Biotempt B.V. | Modulators of PRR and GPCR signalling |
US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
US20170100448A1 (en) | 2014-05-12 | 2017-04-13 | Conatus Pharmaceuticals, Inc. | Treatment of the complications of chronic liver disease with caspase inhibitors |
WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
BR112018013558A2 (pt) | 2015-12-31 | 2018-12-04 | Conatus Pharmaceuticals Inc | método de tratamento de uma doença hepática em um indivíduo, método de uso de um inibidor de caspase, método para diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação de child-pugh ou seus componentes, composição farmacêutica que compreende um inibidor de caspase, kit, método de tratamento, método de tratamento de cirrose hepática e prevenção de uma classificação meld elevada, método de tratamento de cirrose hepática e prevenção de uma classificação de child-pugh elevada |
CA3039283A1 (en) | 2016-10-05 | 2018-04-12 | Novartis Ag | Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
JP2020520981A (ja) * | 2017-05-24 | 2020-07-16 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドRamot At Tel Aviv University Ltd. | プロテアーゼのイメージング/検出のための化学発光プローブ |
WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015577A1 (en) | 1990-04-04 | 1991-10-17 | Black, Roy, A. | INTERLEUKIN 1'beta' PROTEASE |
ATE257517T1 (de) | 1991-08-30 | 2004-01-15 | Vertex Pharma | Interleukin 1-beta protease und ihre inhibitoren |
EP0618223A3 (en) | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
AU5122196A (en) | 1995-03-31 | 1996-10-16 | Takeda Chemical Industries Ltd. | Cysteine protease inhibitor |
EP0900791A1 (en) | 1995-12-27 | 1999-03-10 | Ono Pharmaceutical Co., Ltd. | Tetrazole derivatives and drugs containing the same as the active ingredient |
KR20000036056A (ko) | 1996-09-12 | 2000-06-26 | 아이디유엔 파마슈티칼즈, 인코포레이티드 | 인터루킨-1β 전환 효소 및 관련 프로테아제의 억제제로서의 C-말단 변형된 (N-치환된)-2-인돌릴 디펩티드 |
BR9712530A (pt) | 1996-10-11 | 1999-10-19 | Warner Lambert Co | Inibidores de ésteres de asparato de enzima de conversão de interleucina-1beta |
PL332640A1 (en) * | 1996-10-11 | 1999-09-27 | Warner Lambert Co | Sulphonamide-group substituted derivatives of aspartic acid as inhibitors of an interleukin-1beta transforming enzyme |
AU741203B2 (en) | 1997-10-10 | 2001-11-22 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
US6153591A (en) | 1998-03-16 | 2000-11-28 | Cytovia, Inc. | Dipeptide caspase inhibitors and the use thereof |
US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
EP1165490B1 (en) | 1999-03-16 | 2006-08-16 | Cytovia, Inc. | Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
WO2000061542A1 (en) | 1999-04-09 | 2000-10-19 | Cytovia, Inc. | Caspase inhibitors and the use thereof |
IL148426A0 (en) * | 1999-08-27 | 2002-09-12 | Cytovia Inc | α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
ATE384695T1 (de) * | 2000-03-29 | 2008-02-15 | Vertex Pharma | Carbamat caspase inhibitoren und deren verwendung |
-
2001
- 2001-03-29 AT AT01922868T patent/ATE384695T1/de active
- 2001-03-29 CZ CZ20023227A patent/CZ20023227A3/cs unknown
- 2001-03-29 WO PCT/US2001/010182 patent/WO2001072707A2/en active IP Right Grant
- 2001-03-29 PL PL358430A patent/PL201081B1/pl not_active IP Right Cessation
- 2001-03-29 IL IL15182901A patent/IL151829A0/xx unknown
- 2001-03-29 EA EA200201030A patent/EA005740B1/ru not_active IP Right Cessation
- 2001-03-29 AR ARP010101526A patent/AR027993A1/es active IP Right Grant
- 2001-03-29 AU AU4961901A patent/AU4961901A/xx active Pending
- 2001-03-29 CN CNA2006101685798A patent/CN1994298A/zh active Pending
- 2001-03-29 AU AU2001249619A patent/AU2001249619B2/en not_active Ceased
- 2001-03-29 MX MXPA02009633A patent/MXPA02009633A/es active IP Right Grant
- 2001-03-29 CA CA002403959A patent/CA2403959A1/en not_active Abandoned
- 2001-03-29 KR KR1020027012780A patent/KR100858640B1/ko not_active IP Right Cessation
- 2001-03-29 US US09/821,161 patent/US6689784B2/en not_active Expired - Fee Related
- 2001-03-29 EP EP01922868A patent/EP1268425B1/en not_active Expired - Lifetime
- 2001-03-29 ES ES01922868T patent/ES2296742T3/es not_active Expired - Lifetime
- 2001-03-29 EE EEP200200550A patent/EE200200550A/xx unknown
- 2001-03-29 DE DE60132567T patent/DE60132567T2/de not_active Expired - Lifetime
- 2001-03-29 HU HU0301472A patent/HUP0301472A3/hu unknown
- 2001-03-29 SK SK1392-2002A patent/SK13922002A3/sk unknown
- 2001-03-29 PE PE2001000296A patent/PE20011267A1/es not_active Application Discontinuation
- 2001-03-29 TW TW090107500A patent/TWI318207B/zh not_active IP Right Cessation
- 2001-03-29 PT PT01922868T patent/PT1268425E/pt unknown
- 2001-03-29 BR BR0109588-9A patent/BR0109588A/pt not_active IP Right Cessation
- 2001-03-29 CN CNB018075789A patent/CN100358869C/zh not_active Expired - Fee Related
- 2001-03-29 YU YU73702A patent/YU73702A/sh unknown
- 2001-03-29 DK DK01922868T patent/DK1268425T3/da active
- 2001-03-29 NZ NZ521639A patent/NZ521639A/en not_active IP Right Cessation
- 2001-03-29 JP JP2001570620A patent/JP4298200B2/ja not_active Expired - Fee Related
-
2002
- 2002-09-18 ZA ZA200207483A patent/ZA200207483B/en unknown
- 2002-09-19 IL IL151829A patent/IL151829A/en not_active IP Right Cessation
- 2002-09-23 BG BG107136A patent/BG107136A/bg unknown
- 2002-09-27 NO NO20024661A patent/NO325062B1/no not_active IP Right Cessation
- 2002-09-27 HR HRP20020782 patent/HRP20020782A2/hr not_active Application Discontinuation
-
2003
- 2003-07-02 HK HK03104710.8A patent/HK1052355B/zh not_active IP Right Cessation
- 2003-08-21 US US10/645,043 patent/US7074782B2/en not_active Expired - Fee Related
-
2008
- 2008-06-11 JP JP2008153569A patent/JP2008266348A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200201030A1 (ru) | Карбаматные ингибиторы каспазы и их использование | |
WO2002094263A3 (en) | Caspase inhibitors and uses thereof | |
ATE303988T1 (de) | Inhibitoren von serin proteasen | |
EA200300017A1 (ru) | Ингибиторы серинпротеазы | |
EA200100675A1 (ru) | Ингибиторы протеазы | |
MXPA02011466A (es) | Derivados de fenilglicina.. | |
ATE355284T1 (de) | Inhibitoren von serinproteasen | |
ATE355101T1 (de) | Inhibitoren von serin proteasen | |
NZ509837A (en) | 2-substituted-4-substitued amino-1,2,3,4-tetrahydroquinolines useful as cholesteryl ester transfer protein inhibitors | |
EA200000920A1 (ru) | Производные бициклических гидроксамовых кислот | |
EA200201057A1 (ru) | Новый способ синтеза периндоприла и его фармацевтически приемлемых солей | |
ME00090B (me) | Jedinjenja koja sadrže laktam i njihovi derivati kao inhibitori faktora xa | |
EA200300306A1 (ru) | Спиропиримидин-2,4,6-трионовые ингибиторы металлопротеиназы | |
NZ335981A (en) | Ketobenzamides as calpain inhibitors | |
SE9602646D0 (sv) | Pharmaceutically-useful compounds | |
MY119155A (en) | New peptide derivatives | |
RS50297B (sr) | Fenilfenantridini sa dejstvom inhibicije pde-iv | |
DE69835532D1 (de) | Quinolin-enthaltende alpha-ketoamid-basierte inhibitoren von cystein- und serin protease | |
EA200300836A1 (ru) | Производные фталазинон-пиперидина в качестве ингибиторов pde4 | |
GB0030305D0 (en) | Compounds | |
DE60105418D1 (de) | Serinprotease-inhibitoren | |
TR199801704T2 (xx) | Serin proteaz inhibit�rleri. | |
DE60113252D1 (de) | Inhibitoren von serin proteasen | |
DE69630701D1 (de) | Phosphor enthaltende hemmer von cystein- und serin-proteasen | |
ATE153670T1 (de) | Peptidboronsäurederivate mit protease inhibierenden aktivität |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |